Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: J Cardiovasc Pharmacol. 2015 Jan;65(1):54–61. doi: 10.1097/FJC.0000000000000163

Figure 5.

Figure 5

A, B & C. Effects of chronic erlotinib ± aprepitant treatment for 9 weeks on echocardiographic functional parameters in rats. (A) Left ventricular ejection fraction (LVEF); (B) left ventricular percent fractional shortening (LV % FS); and (C) mitral valve E/A ratio. Rats treated with erlotinib (starting 10 mg/kg/day, oral) and/or aprepitant (starting 2 mg/kg/day, oral) received echocardiography at the indicated intervals. Values for erlotinib ± aprepitant rats were compared to time-matched controls (100%), and are means ± SEM of 5–7 rats per group. * p <0.05 compared with the time-matched control group; a p<0.05 and b p<0.02 versus erlotinib alone.